A calcium blocking and anticholinergic agent (terodiline) in the treatment of detrusor hyperreflexia: a placebo-controlled, cross-over trial.

Abstract

In 25 neurological patients with detrusor hyperreflexia terodiline reduced the number of total micturitions during daytime. Bladder capacity was increased and amplitude of the bladder contractions was reduced. An increase in residual urine was also observed. Mild anticholinergic side-effects were measured on pupillary motility and on heart rate variation. It is concluded that terodiline is a useful alternative in treatment of patients with detrusor hyperreflexia.

• Authors: T Petersen, J Jakobsen
• Journal: Journal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 50 Issue 10 Pg. 1331-6 (Oct 1987) ISSN: 0022-3050 [Print] England
• PMID: 3681312 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Butylamines
• Calcium Channel Blockers
• Parasympatholytics
• terodiline

Topics

• Adult
• Butylamines (therapeutic use)
• Calcium Channel Blockers (therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Parasympatholytics (therapeutic use)
• Random Allocation
• Reflex, Abnormal (drug therapy)
• Urinary Incontinence (drug therapy)
• Urination Disorders (drug therapy)